论文部分内容阅读
艾滋病疫苗在深受HIV流行困扰的非洲地区开始临床使用。在乌干达艾滋病疫苗试用地,目前已确诊感染HIV的人数在乡村居民中已增至10％,在城市居民中增至25％。 这种疫苗是由金丝雀痘病毒衍生而成,金丝雀痘病毒不会在人体复制、致病。在金丝雀痘病毒基础上研制的HIV疫苗,已经给800个美国和法国志愿者接种,证明无严重的副作用。这种疫苗叫ALVAC vCP205,疫苗以减活的金丝雀痘病毒为载体,插人三个HIV病毒基因(无感染活性)。 由国家过敏与感染疾病研究所研制的这种疫苗,在Ⅰ期临床试验中,双盲法随机选择年龄在18～40岁的不携带HIV的健康人40个,这些对象有较低HIV感染危险性,用来检测
AIDS vaccines have started clinical use in Africa, which is plagued by HIV epidemics. At the pilot AIDS vaccine trial in Uganda, the number of confirmed HIV infections has now risen to 10% among rural residents and 25% among urban residents. This vaccine is derived from canary pox virus, canary pox virus does not replicate in the body, causing disease. The HIV vaccine, developed on the basis of canarypox virus, has been given to 800 U.S. and French volunteers, demonstrating no serious side effects. The vaccine, called ALVAC vCP205, is inserted into the three HIV genes (non-infectious) using the live attenuated canarypox virus as a vector. The vaccine, developed by the National Institute of Allergy and Infectious Diseases, was randomized in a Phase I clinical trial to 40 healthy, non-HIV-infected individuals aged 18 to 40 who were at risk for HIV infection Sex, used to test